SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
of Report (Date of earliest event reported): May 6, 2012
(Exact name of registrant as specified in its charter)
|(State or other Jurisdiction of Incorporation)
||(Commission File Number)
||(IRS Employer Identification No.)|
5th Ave, 28th Floor, New York, NY
|(Address of Principal Executive Offices)
telephone number, including area code: (212)-682-8452
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
7.01. Regulation FD Disclosure.
On May 6,
2012, Ohr Pharmaceutical Inc. (the "Company") presented a poster presentation discussing biodistribution and safety
data on the Squalamine eye drop. The poster is attached to this Current Report on Form 8-K as exhibit 99.1 and will be available
on the investor page of the company’s website.
information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This
information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On May 7,
2012, the Company issued a press release announcing the safety and biodistribution results of a preclinical study for the Squalamine
eye drop program presented at ARVO on May 6, 2012.
A copy of
the press release is attached to this Current Report on Form 8-K as exhibit 99.2.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
May 9, 2012||
and CEO |